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Abstract 
4-Amino and 5-amino-cyclopropane pipecolic acids (CPAs) with cis relative stereochemistry between the 
carboxylic and amino groups were used as templates to prepare cyclic peptidomimetics containing the RGD 
sequence as possible integrin binders. The peptidomimetic c(RGD8) built on the 5-amino-CPA displayed an 
inhibition activity (IC50 = 2.4 nM) toward the v3 integrin receptor comparable to that of the most potent 
antagonists reported so far and it was ten times more active than the corresponding antagonist c(RGD7) 
derived from the isomeric 4-amino-CPA. Both compounds were also nanomolar ligands of the 51 integrin. 
These results suggest that the CPA-derived templates are suitable for the preparation of dual v3 and51 
ligands to suppress integrin-mediated events as well as for targeted drug delivery in cancer therapy. 
 
Introduction 
Integrins are cell adhesion transmembrane receptors for extracellular matrix (ECM) proteins, growth 
factors, immunoglobulins, cytokines and matrix-degrading proteases that mediate adhesive events during 
various cancer stages (angiogenesis, tumor growth and progression, invasion, and metastasis).1-3 The V3 
and 51 integrin receptors in particular recognize ECM proteins (e.g. vitronectin and fibronectin) which 
contain an arginine-glycine-aspartic acid (RGD) peptide sequence.4-7 Because of their critical role in tumor-
induced angiogenesis and metastasis formation,8-12 V3 and 51 integrins have received increasing 
attention as therapeutic targets. It has been suggested that targeting 51 in combination with V3 is likely 
to prove more efficient in anticancer therapy. Amongst the various options,13-16 RGD-containing linear and 
cyclic peptides and peptidomimetics have been widely studied as potential antagonists to suppress the 
events mediated by these integrins.14-17 Advantages of cyclic systems are the high stability to chemical 
degradation and, possibly, a higher potency and specificity than linear systems because of their marked 
conformational restraints. To date, a few low-nanomolar-affinity cyclic binders for the V3 receptor have 
been reported which present the RGD system installed on rigid hetero- and carbacyclic scaffolds. For 
example, bicyclic lactams,18-20 -aminocyclopentanecarboxylic acids,21 cis--aminocyclopropanecarboxylic 
acids,22 4-aminoprolines,23,24 bifunctional diketopiperazine,25 and morpholine derivatives,26,27  have all been 
used to generate potent V3 integrin antagonists (compounds 1-6, Figure 1). We have recently reported 
that the 4-amino-substituted CPA (CPA, cyclopropane pipecolic acid) 7 (Figure 2), a new conformationally 
constrained -amino acid prepared from (S)-(+)--hydroxymethyl--butyrolactone, could be successfully 
introduced in a cyclic peptidomimetic [c(RGD7), Figure 2] bearing the RGD sequence.28,29 This derivative 
displayed nanomolar activity as ligand of the V3 integrin in M21 human melanoma cells, suggesting that 
the rigid structure of CPA induces a significant conformational asset towards optimal presentation of the 
pharmacophoric groups of the ligand. Based on these results, since we wanted to establish amino-
substituted CPAs as new rigid platforms for RGD-containing peptidic sequences, we decided to further 
extend our study to other isomeric CPAs and in particular to the corresponding 5-amino-CPA isomer 8 
(Figure 2). We were in fact interested in evaluating whether the different relative position (and spatial 
orientation) of the amino and carboxylic groups on which the RGD sequence is fixed would affect the 
potency of the peptidomimetic against the V3 integrin. At the same time, we were also interested in 
comparing the activity of both peptidomimetics towards the 51 receptor.
30 In this way we could 
determine whether the two templates (7 and 8) would provide an optimal platform for the synthesis of 
integrin ligands as potential therapeutics or for targeted delivery of drugs or diagnostics.13, 31 In this paper 
we thus report on the synthesis of 5-amino-CPA 8 and its cyclic RGD-containing peptidomimetic derivative 
c(RGD8) and the evaluation of both  c(RGD7) and c(RGD8) as ligands of the V3 and 51 receptors 
followed by a comparative conformational analysis.    
 
Results and Discussion 
Synthesis 
The particular absolute configuration of 7 (Figure 2) was chosen on the basis of preliminary molecular 
modeling studies which showed that the RGD sequence in c(RGD7) best overlapped with that of potent 4-
aminoproline derivative 4 (Figure 1).  With 5-amino-CPA derivative 8, which is a -amino acid, it was the 
opposite stereochemistry at C-1 and at the NH2-bearing C atom that provided the best superposition with 
peptidomimetic 4 and for this reason we opted for the inclusion in the cyclic peptidomimetic of this 5-
amino CPA stereoisomer with (1S,5R) absolute configuration. The synthesis of the c(RGD8) peptidomimetic 
is reported in Schemes 1 and 2. The synthesis of racemic alcohol 9 and its enzymatic kinetic resolution (EKR) 
was carried out as already reported.32 Since the resolution provided just less than 50% of the requisite 
enantiopure stereoisomer (S)-9 from the racemic alcohol, butyrate (R)-10 was hydrolyzed and subjected to 
Mitsunobu reaction to invert the C4 configuration and thus increase the amount of the desired 4S 
enantiomer. However, as this reaction was carried out on an allylic alcohol, racemization took place to a 
certain extent and it furnished alcohol (S)-9 with 36% e.e. Thus, for the synthesis of 5-amino-CPA 8 and its 
cyclic peptidomimetic derivative we used (S)-9 as obtained from the EKR, that is with a 94% e.e. (97:3 e.r.) 
relying on the fact that HPLC purification of the final peptidomimetic product would provide a 
diastereopure compound. We first converted (S)-9 into 5-amino CPA methyl ester 11 as reported28 and 
tried to use directly this for assembling the target compound (Scheme 1). However, whilst the coupling of 
the 5-amino group with Z-Asp(OtBu)OH was successful, the selective hydrolysis of the pipecolic CO2Me 
group (necessary to link the Arg-Gly dipeptide) was troublesome. Despite the two protections (methyl and 
t-butyl esters) are generally considered orthogonal, in this molecule this proved untrue and we never 
managed to obtain the free carboxylic group at C1. Thus we changed approach and converted (S)-9 into 
known azide 1328 (Scheme 2), then we carried out the hydrolysis of the methyl ester, the hydrogenation of 
the azide into the amino group and finally the N-Fmoc protection to obtain 16. In this way we could obtain 
an amount of suitable protected amino acid 16 sufficient to accomplish the synthesis of the cyclic 
peptidomimetic. This was carried out (Scheme 2) as already reported for the corresponding 4-amino CPA 
derivative c(RGD7).28  Compared to that, only the final ring closure proved troublesome as it provided, 
besides compound 21, a mixture of other compounds which we were unable to identify but which likely 
contained the minor diastereoisomer deriving from (R)-9 and two dimers. At this stage of the study, we did 
not carry out any other experiment to optimize the final cyclization step by using other coupling 
methodologies and so exhaustive deprotection of the mixture containing compound 21 was carried out. As 
we hoped, we managed to obtain, by semipreparative HPLC, a pure fraction (12% yield over the last two 
steps) of major cyclopeptide c(RGD8) (molecular ion at m/z 525 [M++1]), which was sufficient for the tests 
and the NMR analysis.   
 
Biological tests  
The RGD-containing peptidomimetic c(RGD8) was tested for its integrin binding affinity towards M21 
human melanoma cells expressing high levels of v3 heterodimer
33 as reported for its isomer c(RGD7).28 
The test was carried out in agreement with similar cell-based screening methods, using the same v3 
expressing cell line M21 as reported in the literature, where the reference RGD ligand c[RGDf(Me)V] 
showed an IC50 value of 0.4 nM.
34 Tests were performed in the presence of 2 mM MnCl2, in order to switch 
integrins of tumor cells into an activated form. Both peptidomimetics were also screened for their capacity 
to compete with fibronectin for the binding to 51 integrin expressed by human erythroleukemia cell line 
K562.33 The results are reported in Table 1 and Figure 3. We were pleased to find that the new 
peptidomimetic c(RGD8) proved around ten times more potent than c(RGD7) in inhibiting the binding of 
M21 melanoma cells to vitronectin (IC50 = 2.4 ± 1.8 nM). Interestingly, when both compounds were tested 
as 51 integrin binders, for 5-amino-CPA derivative c(RGD8) we measured an IC50 value of 26 ± 18 nM 
close to the IC50 value  obtained for the c(RGD7) isomer (IC50 = 16 ± 23 nM).   
 
Conformational analysis  
Cyclopeptide c(RGD8) was subjected to conformational analysis to assess the structural determinants 
leading to binding activity towards the integrins. Diluted DMSO-d6 solutions of c(RGD8) were used for the 
NMR analysis in order to prevent aggregation. TOCSY, ROESY and variable temperature 1H NMR 
experiments were carried out for the NMR analysis (Table 2 and Figure 4). Also, molecular modelling 
calculations were carried out to get more insight into the conformational preferences of peptide c(RGD8). 
1H NMR data of diluted DMSO-d6 solution of c(RGD8) showed two sets of signals in a 5 : 1 ratio, as a 
consequence of the existence of rotamers around the N-CO2Me bond (Table S1, Supporting Information). 
The major rotamer showed amide proton chemical shift values between 7.2 and 8.9 ppm, with Asp amide 
proton being the more deshielded, thus suggesting its hydrogen-bonded status (Table 2). Variable 
temperature experiments (Figure 4) indicated low T coefficients for all amide protons, suggesting the 
existence of intramolecular hydrogen-bonds. In contrast to c(RGD7), Asp and Arg amide protons in c(RGD8) 
showed an inverted profile in terms of chemical shift and temperature coefficients, as Asp NH possesses a 
more deshielded chemical shift value and higher T coefficient, possibly resulting from equilibrating 
hydrogen bonding species. Gly NH shows the lowest T coefficient, indicating the involvement in strong 
intramolecular hydrogen bonds. Such data suggest a different intramolecular hydrogen bonding network 
within the two cyclic peptides c(RGD7) and c(RGD8), contributing to a diverse arrangement of the cyclic 
frameworks induced by the two isomeric CPAs (Figure 5). 
Molecular modelling analysis resulted in a global minimum conformer for compound c(RGD8) which 
indicates the role of Gly, CPA and Asp amide protons in establishing equilibrating intramolecular hydrogen-
bonds (Figure 5, bottom right). Specifically, Gly NH experienced a hydrogen-bond with CPA C=O, Asp NH 
with Arg C=O, and CPA NH with Gly C=O, although with variable strength, thus generating two -turns 
within the cyclopeptide. This is in contrast to the conformational asset of c(RGD7), which displayed a 
similarly Arg-centered -turn although stabilized by a -turn having a hydrogen bond experienced by Asp 
NH with CPA C=O (Figure 5, bottom left).  ROESY analysis of c(RGD8) (Figure 5, top right) showed a ROESY 
peak between CPA NH and CPA 3-Hax, and sequential ROESY peaks between Asp NH and Gly H- between 
CPA NH and Asp H-, and between Gly NH and Arg H- consistent with the preferred conformation of 
c(RGD8) found by the modelling and in which the CPA NH points “inwards” below the scaffold’s six-
membered ring. Thus, ROESY peaks together with the variable temperature experiments suggest a 
conformation of the cyclopeptide characterized by the presentation of Asp and Arg side chains as showed 
in Figure 5, right. Although temperature coefficient values indicate that the hydrogen-bonded states could 
be in equilibrium with non hydrogen-bonded states, the existence of a conformation displaying -turns 
suggests CPA nucleating a compact structure in all equilibrating  conformations. The results of the 
conformational analysis and the IC50 values for c(RGD8)  and c(RGD7) indicate a close connection between 
conformational preferences and ligand binding affinity. Specifically, higher ligand binding affinity of 
c(RGD8) resulted from equilibrium between correct conformations for the RGD recognition site of the 
integrin, whereas c(RGD7) showed more rigid structure though not as optimal as the isomeric c(RGD8), 
producing lower affinity towards v3. Such differences in binding affinity was not evinced for 51 integrin, 
suggesting that this integrin best accommodates both RGD peptidomimetics in its recognition site. In all 
cases, the role of CPA in nucleating the correct conformation is due to the existence of the rigid cis 
orientation of amino and carboxylic groups, which allows maintaining the required torsional angles 
between Asp and Arg for an optimal binding to the integrin. 
Based on NMR and conformational studies on integrin ligands, some prerequisites for a robust binding have 
been established amongst which the distance between Arg and Asp beta carbons.14 For V3 integrin 
antagonists, for instance, this distance has an optimal value of 8.9 Å35 which is the distance between the 
beta C atoms in potent antagonist cilengitide c(RGDf[NMe]V) as measured in the X-ray crystal structure of 
the complex with the v3
35,36 and which leads to an extended conformation of the RGD motif and a 
stretched arrangement of the charged side chains. Based on our modelling, the measured distance 
between the two beta C atoms in c(RGD8) is 7.9 Å, that is longer than that calculated for c(RGD7) (7.1 Å) 
and closer to the optimal value, which could account for the higher activity of c(RGD8).  On the other hand, 
the high potency of both c(RGD7) and c(RGD8) towards 51 integrin is justified by the fact that the binding 
mode is the same as in V3 and that the requisite distance between the beta C atoms for an optimal 
binding with 51 is in the same range.
7,14,37-39  
It is worth to notice that v3 vs. 51 selectivity is observed in many RGD-containing cyclic peptides and 
peptidomimetics. For example cyclo-(-Arg-Gly-Asp-D-Phe-Val-),40 and compounds 119 and 322 (Figure 1) are 
all v3 selective ligands, and the same Cilengitide cyclo-[-Arg-Gly-Asp-D-Phe-(N-Me)Val-] shows sub-
nanomolar (0.65 nM) activity for the v3  receptor and nanomolar (13.2 nM) affinity for 51. Extra N-
methylation of Cilengitide further increases the  v3 / 51 selectivity by 2-3 orders of magnitudes.
41 In all 
these cases the selectivity has been shown to depend on the overall conformation of the cyclopeptide. Our 
compounds are instead not selective, as they display the same nanomolar potency toward both integrins.42 
For cyclopeptides like 3 (Figure 1) incorporating a -aminocyclopropane amino acid, v3 selectivity has 
been explained on the basis of a less stretched conformation of the RGD sequence, as suggested by a 
shorter distance between the C atoms of Arg and Asp (from 5.25 to 6.50 Å in 3). In a non-selective isomer 
of 3, this distance is 6.00-7.00 Å corresponding to a more stretched conformation for the RGD sequence.22 
For c(RGD7) and c(RGD8) the distances between the C atoms of Arg and Asp are 6.01 and 6.07 Å, which 
are at the borderline of the two ranges above mentioned, and therefore the lack of selectivity cannot be 
correlated with such a parameter.  
 
Conclusion 
In conclusion, both 4-amino and 5-amino-cyclopropane pipecolic acids (CPAs) with cis relative 
stereochemistry between the carboxylic and the amino groups are suitable templates to prepare cyclic 
peptidomimetics containing the RGD sequence and which are potent ligands of both v3 and 51 integrin 
receptors. The RGD-containing peptidomimetic c(RGD8) built on the 5-amino-CPA displayed an inhibition 
activity toward v3 (IC50 = 2.4 nM) comparable to that of the most potent antagonists reported so far and 
it was also around ten times more active than the corresponding ligand c(RGD7) derived from the isomeric 
4-amino-CPA. Since the activity of both compounds was in the nanomolar range towards both  integrins, 
c(RGD7) and c(RGD8) can be considered as dual ligands, which could be an advantage in these compounds 
finding applications in anticancer therapy. These results are encouraging in further employing these CPA 
templates for the synthesis of new integrin binders and, by exploiting the scaffold nitrogen atom as an 




Chromatographic separations were performed under pressure on silica gel 60 (Merck,70–230 mesh) using 
flash column techniques; Rf values refer to TLC carried out on 0.25 mm silica gel plates with the same 
eluent indicated for column chromatography. 1H NMR (500, 400 and 200 MHz) and 13C NMR (50.33 and 
100.4 MHz) spectra were recorded on Bruker Avance II 500 MHz Ultrashield,  and Varian Inova and Mercury 
spectrometers in CDCl3 at 25 °C unless otherwise stated. Mass spectra were carried out by direct inlet on a 
LCQ FleetTM Ion Trap LC/MS system (Thermo Fisher Scientific) with an ESI interface in the positive mode. 
Ligand c(RGD8) was purified by Beckman-Gold HPLC system equipped with a reverse-phase semi-
preparative column (Alltima C18 10 μm, 250 mm × 10 mm, Alltech). Analytical HPLC analyses were 
performed on Dionex Ulltimate 3000 system equipped with a reverse-phase column (Acclaim 120, C18, 5 
μm, 4.6-250 mm). Anhydrous solvents were either commercial or prepared according to standard 
techniques. 
 
5-[Z-Asp(OtBu)]-2-(methoxycarbonyl)-5-NHCPA-OMe  [12] 
DEPBT (347 mg, 1.16 mmol) and DIPEA (202 L, 1.16 mmol) were added to a solution of Z-Asp(OtBu)-
OH·H2O (273 mg, 0.80 mmol) in anhydrous THF (3.5 mL) cooled to 0 °C, under N2 atmosphere, and the 
resulting mixture was allowed to rise to room temperature. After 15 min this solution was slowly added to 
a solution of compound 11 (92 mg, 0.40 mmol) in anhydrous THF (3 mL) pre-cooled to 0 °C. The resulting 
reaction mixture was stirred at 35 °C for 6 days. Afterward, EtOAc (20 mL) was added and the mixture was 
washed with a satd. solution of NH4Cl (10 mL), a satd. solution of NaHCO3 (10 mL) and H2O (10 mL). The 
organic layer was dried over Na2SO4, filtered and evaporated under vacuum. The residue was purified by 
flash chromatography (n-hexane/EtOAc 1:1, Rf 0.23) affording pure 12 (178 mg, 84 %) as a white solid. 
M.p. 62.7-66.0 °C. [α]D
21 +16.6  (c 1.40, CHCl3) (ee 94%). 
1H NMR (400 MHz, CDCl3) (mixture of rotamers) δ 
(ppm): 7.38-7.30 (m, 5 H, Ph, both rotamers), 7.00-6.90 (m, 1 H, NH CPA, both rotamers), 6.02-5.90 (m, 1 H, 
NH Asp, both rotamers), 5.11 (s, 2 H, CH2Ph, both rotamers), 4.55-4.44 (m, 1 H, Hα Asp, both rotamers), 
4.18-4.05 (m, 1 H, 5-H, both rotamers), 3.88-3.81 (m, 1 H, 3-Heq, major rotamer), 3.75-3.62 (m, 7 H, 3-Heq 
minor rotamer + 2 x OCH3 both rotamers), 3.06-2.98 (m, 1 H, 3-Hax, minor rotamer), 2.94-2.84 (m, 2 H, 3-Hax 
major rotamer + Hβ Asp both rotamers), 2.59 (dd, J = 17.2, 7.4 Hz, 1 H, Hβ’ Asp, both rotamers), 1.97 (dd, J = 
10.0, 5.7 Hz, 1 H, 7-H, minor rotamer), 1.90 (dd, J = 10.1, 5.4 Hz, 1 H, 7-H, major rotamer), 1.68-1.56 (m, 3 
H, 4-H + 4-H’ + 6-H, both rotamers), 1.42 [s, 9 H, OC(CH3)3], 0.92-0.84 (m, 1 H, 7-H’, both rotamers). 
13C NMR 
(100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.2, 171.2, 169.9, 156.9, 156.1, 135.9 (Carom), 128.6 (2 C, 
Carom), 128.3 (2 C, Carom), 128.1 (Carom), 82.0 [OC(CH3)3], 67.3 (CH2Ph), 53.0 (OCH3), 52.5 (OCH3), 50.9 (Cα Asp), 
43.1, 38.3, 37.9, 37.7 (Cβ Asp), 29.1, 28.0 [3 C, OC(CH3)3], 27.8, 21.3. MS (ESI) m/z (%): 1089 (22) [2M + Na]
+, 
556 (100) [M + Na]+. C26H35N3O9 (533.57): calcd. C, 58.53; H, 6.61; N, 7.88. Found: C, 58.64; H, 6.33; N, 7.62. 
 
(1S,5R,6S)-5-Azido-2-(methoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid  [14] 
A 1 N solution of NaOH (1.23 mL) was added to a solution of 13 (208 mg, 0.82 mmol) in MeOH (2 mL) and 
the resulting mixture was vigorously stirred for 24 h at room temperature. Afterward, the methanol was 
evaporated and the remaining aqueous layer was washed with Et2O (5 mL). Then, the aqueous layer was 
acidified to pH 3, adding a 1 N solution of HCl, and the product was extracted with CHCl3 (5 x 5 mL). Finally, 
the aqueous layer was further acidified to pH 1 and the product was extracted again with CHCl3 (5 x 5 mL). 
The combined organic layers were dried over Na2SO4 and after filtration and evaporation of the solvent, 
compound 14 (183 mg, 93%) was obtained as a white solid. 
[α]D
21 +30.7  (c 0.98, CHCl3) (e.e. 94%). 
1H NMR (400 MHz, CDCl3) (1.5:1 mixture of rotamers) δ (ppm): 10.21 
(bs, 1 H, COOH), 4.04-4.00 (m, 1 H, 5-H, both rotamers), 3.89 (dt, J = 11.3, 4.1 Hz, 1 H, 3-Heq, major 
rotamer), 3.78-3.69 (m, 4 H, 3-Heq minor rotamer + OCH3 both rotamers), 3.07 (t, J = 11.9 Hz, 3-Hax, minor 
rotamer), 2.97 (t, J = 11.3 Hz, 3-Hax, major rotamer), 2.06-1.87 (m, 2 H, 6-H + 7-Hexo, both rotamers), 1.82-
1.75 (m, 1 H, 4-H, both rotamers), 1.60-1.52 (m, 1 H, 4-H’, both rotamers), 0.95-0.88 (m, 1 H, 7-Hendo, both 
rotamers). 13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 177.2 (CO), 156.9 (NCO), 54.7 (C-5), 53.2 
(OCH3), 38.0, 36.7, 28.6, 27.6, 21.5. MS (ESI) m/z (%): 239 (100) [M – 1]
–. C9H12N4O4 (240.22): calcd. C, 45.00; 
H, 5.04; N, 23.32. Found: C, 45.21; H, 4.87; N, 23.01. 
 
 
(1S,5R,6S)-5-Amino-2-(methoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-carboxylic acid  [15] 
10% Pd/C (24 mg) was added to a solution of 14 (183 mg, 0.76 mmol) in anhydrous MeOH (15 mL), under 
N2 atmosphere. The resulting suspension was stirred vigorously under H2 atmosphere (balloon) at room 
temperature. During the reaction, the resulting product precipitated, due to the formation of the 
zwitterion. After 24 h, H2O (100 mL) was added and the resulting mixture was filtered over a celite layer. 
After evaporation of the solvent, pure 15 (123 mg, 67%) was obtained as a white solid, directly used in the 
next step without further purifications. 
1H NMR (400 MHz, D2O) (2:1 mixture of rotamers) δ (ppm): 3.79-3.72 (m, 1 H, 3-Heq, both rotamers), 3.71 
(s, 3 H, OCH3, minor rotamer), 3.70 (s, 3 H, OCH3, major rotamer), 3.62-3.58 (m, 1 H, 5-H, major rotamer), 
3.57-3.54 (m, 1 H, 5-H, minor rotamer), 3.20-3.07 (m, 1 H, 3-Hax, both rotamers), 1.84-1.77 (m, 3 H, 4-H + 
4-H’ + 7-H, both rotamers), 1.69-1.61 (m, 1 H, 6-H, both rotamers), 0.94-0.87 (m, 1 H, 7-H’, both rotamers). 
MS (ESI) m/z (%): 215 (67) [M + 1]+. 
 
(1S,5R,6S)-5-(9-Fluorenylmethoxycarbonylamino)-2-(methoxycarbonyl)-2-azabicyclo[4.1.0]heptane-1-
carboxylic acid  [16] 
A 10% aqueous solution of Na2CO3 (1.6 mL) was added to a suspension of amino acid 15 (120 mg, 0.56 
mmol) in THF (1.3 mL). The resulting mixture was cooled to 0 °C and added with a solution of Fmoc-OSu 
(189 mg, 0.56 mmol) in THF (3.8 mL). The reaction mixture was vigorously stirred at room temperature for 
24 h. Afterward, the solvent was evaporated under vacuum and the residue was taken up in EtOAc (6 mL). 
Then, a satd. solution of NH4Cl (6 mL) was added and the product was extracted with EtOAc (5 x 6 mL). The 
aqueous layer was acidified to pH 2, adding a 1 N solution of HCl, and the product was extracted again with 
EtOAc (5 x 6 mL). The combined organic layers were dried over Na2SO4. After filtration and evaporation of 
the solvent the crude was purified by flash chromatography (MeOH/CH2Cl2 1:20, then MeOH/CH2Cl2 1:10, Rf 
0.38) to afford compound 16 (197 mg, 81%) as a white solid. 
M.p. 171-173 °C (dec). [α]D
22 –16.1  (c 1.60, CHCl3) (e.e. 94%). 
1H NMR (400 MHz, CD3OD) (mixture of 
rotamers) δ (ppm):  7.76 (d, J = 7.5 Hz, 2 H, Fmoc), 7.63-7.61 (m, 2 H, Fmoc), 7.36 (t, J = 7.5 Hz, 2 H, Fmoc), 
7.28 (t, J = 7.5 Hz, 2 H, Fmoc), 4.40-4.32 (m, 2 H, CH2 Fmoc), 4.16 (bs, 1 H, CH Fmoc), 3.81 (bs, 1 H, 5-H), 
3.75-3.60 (m, 4 H, 3-Heq + OCH3), 3.09-3.00 (m, 1 H, 3-Hax), 1.79-1.76 (m, 1 H, 7-H), 1.66-1.56 (m, 3 H, 4-H + 
4-H’ + 6-H), 0.78-0.70 (m, 1 H, 7-H’). 13C NMR (100.4 MHz, CD3OD) (major rotamer) δ (ppm): 159.3 (Cq), 
158.8 (Cq), 158.1 (Cq), 145.3 (2 C, Cq,arom), 142.6 (2 C, Cq,arom), 128.7 (2 C, Carom), 128.1 (2 C, Carom), 126.1 (2 C, 
Carom), 121.0 (2 C, Carom), 67.4 (CH2 Fmoc), 53.3 (OCH3), 48.5 (CH Fmoc), 46.1 (C-5), 40.5 (C-4), 39.0 (C-3), 
29.2 (C-6), 29.0 (C-4), 21.0 (C-7). MS (ESI) m/z (%): 435 (100) [M – 1]–. C24H24N2O6 (436.46): calcd. C, 66.04; 
H, 5.54; N, 6.42. Found: C, 66.23; H, 5.29; N, 6.09. 
 
 
5-Fmoc-[2-(Methoxycarbonyl)-5-NHCPA]-Arg(Mtr)-Gly-OBn  [17] 
DEPBT (138 mg, 0.46 mmol) and DIPEA (80 L, 0.46 mmol) were added to a solution of 16 (100 mg, 0.23 
mmol) in anhydrous THF (2 mL) cooled to 0 °C, under N2 atmosphere, and the resulting mixture was 
allowed to rise to room temperature. After 15 min the reaction was cooled again to 0 °C and a solution of 
H-Arg(Mtr)-Gly-OBn (184 mg, 0.35 mmol) in anhydrous THF (2.5 mL) was added. The resulting reaction 
mixture was stirred at 35 °C for 4 days. Afterward, EtOAc (35 mL) was added and the mixture was washed 
with a satd. solution of NH4Cl (2 x 9 mL), a satd. solution of NaHCO3 (2 x 9 mL) and H2O (2 x 9 mL). The 
organic layer was dried on Na2SO4, filtered and evaporated under vacuum. The residue was purified by flash 
chromatography (EtOAc, Rf 0.59) affording pure 17 (172 mg, 79 %) as a white solid. 
M.p. 110-130 °C (dec.). [α]D
21 –5.8  (c 0.80, CHCl3). 
1H NMR (400 MHz, CD3OD) (2:1 mixture of rotamers) δ 
(ppm): 8.41-8.36 (m, 1 H, NH Gly, minor rotamer), 8.15 (bs, 2 H, NH Gly + NH Arg, major rotamer), 7.90-7.86 
(m, 1 H, NH Arg, minor rotamer), 7.76 (d, J = 7.4 Hz, 2 H, Fmoc, both rotamers), 7.60 (t, J = 7.1 Hz, 2 H, 
Fmoc, both rotamers), 7.37-7.25 (m, 9 H, Fmoc + Ph, both rotamers), 6.65 (s, 1 H, CH Mtr, minor rotamer), 
6.60 (s, 1 H, CH Mtr, major rotamer), 5.17-5.12 (m, 2 H, CH2Ph, both rotamers), 4.41-4.35 (m, 3 H, Hα Arg + 
CH2 Fmoc, both rotamers), 4.17-4.05 (m, 2 H, Hα Gly + CH Fmoc, both rotamers), 4.02-3.84 (m, 2 H, Hα Gly + 
5-H, both rotamers), 3.81 (s, 3 H, OCH3 Mtr, minor rotamer), 3.79-3.74 (m, 4 H, 3-Heq both rotamers + OCH3 
Mtr major rotamer), 3.66 (bs, 3 H, OCH3, both rotamers), 3.23-2.90 (m, 3 H, 3-Hax + Hδ Arg, both rotamers), 
2.67 (s, 3 H, CH3 Mtr, minor rotamer), 2.66 (s, 3 H, CH3 Mtr, major rotamer), 2.61 (s, 3 H, CH3 Mtr, minor 
rotamer), 2.59 (s, 3 H, CH3 Mtr, major rotamer), 2.11 (s, 3 H, CH3 Mtr, minor rotamer), 2.07 (s, 3 H, CH3 Mtr, 
major rotamer), 1.99-1.42 (m, 8 H, 4-H + 4-H’ + 6-H + 7-H + Hβ Arg + Hγ Arg, both rotamers), 0.81-0.72 (m, 1 
H, 7-H’). 13C NMR (100.4 MHz, CD3OD) (major rotamer) δ (ppm): 174.8, 173.8, 171.7, 159.8, 159.1, 158.1, 
157.9, 145.3 (2 C, Carom), 142.6 (2 C, Carom), 139.5 (Carom), 137.8 (Carom), 137.1 (Carom), 134.8 (Carom), 129.6 (2 C, 
Carom), 129.3 (Carom), 128.7 (2 C, Carom), 128.3 (Carom), 128.1 (Carom), 128.0 (2 C, Carom), 126.1 (2 C, Carom), 125.7 
(Carom), 120.9 (2 C, Carom), 112.7 (Carom), 68.0 (CH2Ph), 67.5 (CH2 Fmoc), 55.9 (OCH3 Mtr), 54.6, 53.9 (OCH3), 
48.5 (CH Fmoc), 45.2, 44.8, 42.0 (Cα Gly), 41.7, 39.5, 29.8, 29.3, 28.9, 27.1, 24.4 (CH3 Mtr), 20.8, 18.9 (CH3 
Mtr), 12.1 (CH3 Mtr). MS (ESI) m/z (%): 1926 (9) [2M + Na]
+, 974 (100) [M + Na]+.  
 
5-Amino-[2-(methoxycarbonyl)-5-NHCPA]-Arg(Mtr)-Gly-OBn  [18] 
Compound 17 (170 mg, 0.18 mmol), was dissolved in a 1:1 CH2Cl2/DEA mixture (2.25 mL), under N2 
atmosphere. The resulting solution was stirred at room temperature for 4 h, meanwhile additional 1:1 
DCM/DEA mixture (1.13 mL) was added. Afterward, the solution was concentrated under vacuum, the 
residue was taken up in CH2Cl2 (6 mL) and then concentrated again. The crude was purified by flash 
chromatography (EtOAc, then MeOH/EtOAc 1:1, Rf 0.18), affording pure 18 (129 mg, 99 %) as a white solid. 
M.p. 160 °C (dec.). [α]D
19 –3.6  (c 0.92, CH3OH).  
1H NMR (400 MHz, CD3OD) (major rotamer) δ (ppm): 7.35-
7.30 (m, 5 H, Ph), 6.65 (s, 1 H, CH Mtr), 5.16 (s, 2 H, CH2Ph), 4.42-4.39 (m, 1 H, Hα Arg), 4.12-3.90 (m, 2 H, Hα 
Gly), 3.82 (s, 3 H, OCH3 Mtr), 3.71-3.60 (m, 4 H, 3-Heq + OCH3), 3.35-3.10 (m, 4 H, 3-Hax + 5-H + Hδ Arg), 2.67 
(s, 3 H, CH3 Mtr), 2.61 (s, 3 H, CH3 Mtr), 2.12 (s, 3 H, CH3 Mtr), 1.98-1.82 (m, 3 H, 7-H + Hγ Arg), 1.71-1.48 (m, 
5-H, 4-H + 4-H’ + 6-H + Hβ Arg), 0.80-0.72 (m, 1 H, 7-H’). 
13C NMR (100.4 MHz, CD3OD) (major rotamer) δ 
(ppm): 174.8, 174.0, 171.9, 159.8, 158.2, 142.7 (Carom), 139.4 (Carom), 137.8 (Carom), 137.1 (Carom),, 134.8 
(Carom), 129.5 (2 C, Carom), 129.3 (Carom), 128.3 (Carom), 125.7 (2 C, Carom), 112.7 (Carom), 68.0 (CH2Ph), 56.0 
(OCH3 Mtr), 54.5, 53.9 (OCH3), 45.0, 42.0, 41.8, 39.0, 31.4, 30.7, 30.3, 29.3, 27.0, 24.3 (CH3 Mtr), 20.9, 18.8 
(CH3 Mtr), 12.1 (CH3 Mtr). MS (ESI) m/z (%): 1459 (18) [2M + 1]
+, 752 (17) [M + Na]+, 731 (42), 730 (100) [M 
+ 1]+.  
 
5-[Z-Asp(OtBu)]-2-(methoxycarbonyl)-5-NHCPA-Arg(Mtr)-Gly-OBn [19] 
DEPBT (108 mg, 0.36 mmol) and DIPEA (63 L, 0.36 mmol) were added to a solution of Z-Asp(OtBu)-OH·H2O 
(85 mg, 0.25 mmol) in anhydrous THF (2 mL) cooled to 0 °C, under N2 atmosphere, and the resulting 
mixture was allowed to rise to room temperature. After 15 min this solution was slowly added to a solution 
of compound 18 (120 mg, 0.16 mmol) in anhydrous THF (1 mL) pre-cooled to 0 °C. The resulting reaction 
mixture was stirred at 35 °C for 4 days. Afterward, EtOAc (20 mL) was added and the mixture was washed 
with a satd. solution of NH4Cl (2 x 5 mL), a satd. solution of NaHCO3 (2 x 5 mL) and H2O (2 x 5 mL). The 
organic layer was dried over Na2SO4, filtered and evaporated under vacuum. The residue was purified by 
flash chromatography (EtOAc, Rf 0.40) affording pure 19 (84 mg, 49 %) as a white solid. 
M.p. 110 °C (dec.). [α]D
21 +22.4  (c 0.84, CHCl3).  
1H NMR (400 MHz, CDCl3) (major rotamer) δ (ppm): 7.78 
(bs, 1 H, NH Gly), 7.68-7.40 (m, 1 H, NH CPA), 7.36-7.12 (m, 10 H, 2 x Ph), 7.18-7.05 (m, 1 H, NH Arg), 6.50 
(s, 1 H, CH Mtr), 6.28-5.96 (m, 4 H, NHε Arg + NH Asp), 5.16-4.96 (m, 4 H, 2 x CH2Ph), 4.61-4.40 (m, 2 H, Hα 
Asp + Hα Arg), 4.26 (bs, 1 H, 5-H), 4.16-3.98 (m, 2 H, Hα Gly), 3.90-3.74 (m, 4 H, 3-Heq + OCH3 Mtr), 3.64 (s, 3 
H, OCH3), 3.28-2.90 (m, 3 H, 3-Hax + Hδ Arg), 2.75-2.65 (m, 5 H, Hβ Asp + CH3 Mtr), 2.60 (s, 3 H, CH3 Mtr), 2.11 
(s, 3 H, CH3 Mtr), 2.04-1.86 (m, 3 H, 7-H + Hβ Arg), 1.78-1.50 (m, 5 H, 4-H + 4-H’ + 6-H + Hγ Arg), 1.37 (s, 9 H, 
OC(CH3)3), 0.72-0.68 (m, 1 H, 7-H’). 
13C NMR (100.4 MHz, CDCl3) (major rotamer) δ (ppm): 172.4, 171.6, 
170.2, 169.8, 158.3, 157.5, 156.3, 156.0, 138.4 (Carom), 136.4 (Carom), 136.1 (Carom), 135.1 (Carom), 135.0 (Carom), 
133.3 (Carom), 128.5 (2 C, Carom), 128.4 (2 C, Carom), 128.3 (Carom), 128.2 (2 C, Carom), 128.1 (2 C, Carom), 127.8 
(Carom), 124.7 (Carom), 111.6 (CHarom), 81.4 [OC(CH3)3], 67.0 (CH2Ph), 66.8 (CH2Ph), 55.3 (OCH3 Mtr), 53.3 
(OCH3), 52.8 (Cα Arg), 51.3 (Cα Asp), 42.7 (C-5), 41.1 (Cα Gly), 40.4 (Cδ Arg), 38.3 (C-3), 37.9 (Cβ Asp), 29.6 (Cβ 
Arg), 29.1, 28.3 (C-6), 27.8 [3 C, OC(CH3)3], 27.4 (C-4), 25.1 (Cγ Arg), 24.0 (CH3 Mtr), 20.0 (C-7), 18.3 (CH3 
Mtr), 11.8 (CH3 Mtr). MS (ESI) m/z (%): 1057 (100) [M + Na]




10% Pd/C (30 mg) was added to a solution of 19 (84 mg, 0.08 mmol) in ethanol (4 mL), under N2 
atmosphere. The resulting suspension was stirred under H2 atmosphere (balloon) at room temperature for 
24 h. After filtration over a celite layer and evaporation of the solvent, compound 20 (59 mg, 91%) was 
obtained as a white solid. This crude was suspended in THF (20 mL), under N2 atmosphere. The suspension 
was cooled to 0 °C and DEPBT (64 mg, 0.21 mmol) and DIPEA (37 L, 0.21 mmol) were added. The resulting 
reaction mixture was stirred at 35 °C for 4 days. Afterward, EtOAc (10 mL) was added and the mixture was 
washed with a satd. solution of NH4Cl (5 mL), a satd. solution of NaHCO3 (5 mL) and H2O (5 mL). The organic 
layer was dried on Na2SO4, filtered and evaporated under vacuum. The residue was purified by flash 
chromatography (EtOAc, then MeOH/EtOAc 1:4, Rf 0.60) affording 21 in mixture with other unidentified 
products (21 mg) and as a white solid. 
1H NMR (400 MHz, CD3OD)  (major product, major rotamer) δ (ppm): 6.66 (s, 1 H, CH Mtr), 4.69-4.61 (m, 1 
H, Hα Asp), 4.53-4.43 (m, 1 H, 5-H), 4.30-4.23 (m, 1 H, Hα Arg), 4.07-3.96 (m, 1 H, Hα Gly), 3.93-3.80 (m, 4 H, 
3-Heq + OCH3 Mtr), 3.78-3.63 (m, 3 H, OCH3), 3.46 (d, J = 13.6 Hz, 1 H, Hα Gly), 3.23-3.07 (m, 2 H, Hδ Arg), 
2.94-2.76 (m, 3 H, 3-Hax + Hβ Asp), 2.65 (s, 3 H, CH3 Mtr), 2.62-2.45 (m, 4 H, Hβ Asp + CH3 Mtr), 2.11 (s, 3 H, 
CH3 Mtr), 1.96-1.47 (m, 7 H, 4-H + 4-H’ + 7-H + Hβ Arg + Hγ Arg), 1.41 (s, 9 H, OC(CH3)3), 1.33-1.22 (m, 1 H, 6-
H), 0.87-0.66 (m, 1 H, 7-H’).  MS (ESI) m/z (%): 815 (36), 794 (37), 793 (100) [M + 1]+.  
 
Cyclo[Arg-Gly-Asp-2-(methoxycarbonyl)-5-NHCPA]·TFA [c(RGD8)] 
Protected tetrapeptide 21 (21 mg, 0.026 mmol) was dissolved in a 95:2.5:2.5 TFA/TIS/H2O mixture (1.25 
mL) and the resulting solution was stirred at room temperature for 18 h. Afterward, the mixture was 
evaporated under vacuum and the residue was taken up in H2O (2 mL) and washed with Et2O (4 x 700 L). 
Then, the aqueous layer was concentrated under vacuum, affording the deprotected cyclic tetrapeptide as 
a trifluoroacetate salt. This crude was purified by semi-preparative HPLC (C18 column, 10 m, 250 mm × 10 
mm) using acetonitrile (0.1% TFA) in H2O (0.1% TFA), 0-50% linear gradient over 35 min at room 
temperature. A flow rate of 2 mL/min was used and detection was at 223 nm. HPLC Rt = 25.4 min. The HPLC 
sample was concentrated under vacuum and lyophilized, affording pure c(RGD8) (5.6 mg, 12% from 20) as a 
colourless glassy solid. Purity checked by HPLC analysis (C18 column, 5 μm , 4.6-250 mm), using acetonitrile 
(0.1% TFA) in water (0.1% TFA) as eluant, 5-35% linear gradient over 35 min at room temperature. 
1H NMR (500 MHz, DMSO) (5:1 mixture of rotamers) (major rotamer) δ (ppm): 8.88 (d, J = 7.6 Hz, NH Asp), 
7.77 (d, J = 8.1 Hz, NH CPA), 7.53-7.47 (m, NH Arg), 7.24-7.20 (m, NH Gly), 7.19-6.64 (m, 4 H, NHε Arg), 4.52-
4.46 (m, 1 H, Hα Asp), 4.16-4.11 (m, 1 H, 5-H), 4.04-3.95 (m, 1 H, Hα Gly), 3.86-3.79 (m, 1 H, 3-Heq),  3.66-
3.59 (m, 4 H, Hα Arg + OCH3), 3.34-3.26 (m, 1 H, Hα Gly), 3.12-3.02 (m, 2 H, Hδ Arg), 2.99-2.87 (m, 1 H, 3-Hax), 
2.82 (dd, J = 16.5, 9.0 Hz, 1 H, Hβ Asp), 2.45 (dd, J = 16.5, 6.1 Hz, 1 H, Hβ Asp), 1.99-1.81 (m, 2 H, Hβ Arg), 
1.67-1.60 (m, 1 H, 7-H), 1.55-1.46 (m, 2 H, 4-H), 1.44-1.36 (m, 2 H, Hγ Arg), 1.36-1.29 (m, 1 H, 6-H), 0.83-0.71 
(m, 1 H, 7-H’). MS (ESI) m/z (%): 526 (26), 525 (100) [M + 1]+. C23H33F3N8O10 (638.55): calcd. C, 43.26; H, 
5.21; N, 17.55. Found: C, 43.48; H, 5.02; N, 17.23. 
 
 
Biological assays  
v3 and 51 integrin binding assays 
Cell lines and culture conditions. The M21 human melanoma cell line (for v3 binding assays) was 
obtained from the American Type Culture Collection (ATCC, Rockville, MD). Melanoma cells were grown in 
Dulbecco’s modified Eagle medium, containing 4500 mg/L glucose (DMEM 4500, GIBCO) supplemented 
with 10% foetal calf serum (FCS) at 37 °C in a humidified incubator containing 10% CO2. 5x10
5 melanoma 
cells were seeded in 100 mm Sarstedt dishes and propagated every 3 days by incubation with a 
trypsin−EDTA solution. The human erythroleukemia cell line K562 (for 51 binding assays) was maintained 
in Iscove's Modified Dulbecco's Medium (IMDM, GIBCO) supplemented with 10% FCS in T25 culture flasks 
(Sarstedt) in humidified incubator at 37°C, 5% CO2. When cultures reached a cell density between 1x10
5 
and 1x106 cells/mL cells were re-suspended in warm fresh media at a volume to yield a density of 2x105 
cells/mL. Both M21 and K562 cultures were periodically monitored for mycoplasma contamination.  
Citofluorimetric assay. M21 cells were detached by gentle treatment with Accutase (Lonza), a 0.5 mM 
EDTA solution. K562 cells were removed from culture flasks and re-suspended in fresh medium. Cells were 
then washed, and incubated for 1 h at 4°C in the presence of anti-vβ3 monoclonal antibody (1 μg/50 μL, 
anti-integrin vβ3, clone LM609, Millipore), anti-vβ5 monoclonal antibody (1 μg/50 μL, anti-integrin vβ5, 
Santa Cruz 13588) and anti 51 monoclonal antibody (1 μg/50 μL, anti-integrin 5β1, Abcam ab75472) . 
Cells were then washed and incubated for 1 h at 4 °C with a specific secondary antibody, 5 μg/mL goat 
antimouse IgG conjugated with FITC (Santa Cruz Biotecnology, Inc., Santa Cruz, CA). Integrin-Positive cells 
were analyzed at 488 nm on the flow cytometer FACScan system (BD-FACS Canto). 
Cell adhesion assay. The plates (96 wells) containing M21 (for v3 binding assays) or K562 (for 51 
binding assays) cells were coated with vitronectin (for v3 binding assays, 10 μg/mL) or fibronectin (for 
51 binding assays, 10 μg/mL)  (both from Sigma) by overnight incubation at 4 °C. Plates were washed with 
PBS and then incubated at 37 °C for 1 h with PBS−1% BSA. After being washed cells were counted and re-
suspended in serum free medium, and exposed to compound (final concentration was in the 30 M to 1 
nM range for 51 binding assays, and in the 30 M to 10 nM range for 51 binding assays) at 37 °C for 30 
min to allow the ligand-receptor equilibrium to be reached. Assays were performed in the presence of 2 
mmol/L MnCl2. Cells were then plated (4−5×10
4 cells/well) and incubated at 37 °C for 1 h. All the wells were 
washed with PBS to remove the non-adherent cells, and 0.5% crystal violet solution in 20% methanol was 
added. After 2 h of incubation at 4 °C, plates were examined at 540 nm in a counter ELX800 (Bio TEK 
Instruments). Experiments were conducted in triplicate and were repeated at least three times. The values 
are expressed as % inhibition ± SEM of cell adhesion relative to untreated cells.  
Data Analysis. The IC50 values were determined by fitting binding inhibition data by non-linear regression 
using GraphPad Prism 4.0 Software Package (GraphPad Prism, San Diego, CA). 
 
NMR Methods 
NMR experiments on diluted DMSO-d6 solutions of c(RGD8) were performed at a temperature of 298 K on 
a Varian Mercury 400 MHz NMR spectrometer and on a Bruker Avance II 500 MHz Ultrashield. All proton 
chemical shifts were assigned unambiguously for c(RGD8). Variable temperature 1D, and 2D experiments 
(TOCSY, gCOSY, ROESY) were carried out at the sample concentration of 3 mM for c(RGD8). One-
dimensional 1H NMR spectra for determining temperature coefficients were obtained at 298–323 K with 
increments of 5 K. Sample temperatures were controlled with the variable-temperature unit of the 
instrument. Proton signals were assigned via TOCSY spectra, and ROESY spectra provided the data 
discussed in the conformational analysis. TOCSY spectra were recorded with 2048 points in t1, 256 points in 
t2, and 16 scans per t2 increment and using a mixing time of 80 ms. ROESY spectra were recorded with a 
similar number of t1 and t2 points unless otherwise noted, and 64 scans per t2 increment, and using a 
spinlock of 0.2 s.  
 
Molecular Modelling 
Molecular modeling calculations were carried out within the framework of Macromodel v6.5,43 using 
Amber*44 as a force field and the implicit water GB/SA solvation model of Still et al.45 Monte Carlo energy 
minimization (MCEM)46 conformational searches of the peptide analogue containing methyl groups instead 
of the Arg and Asp side chains were performed as the first step. The torsional space of each AGA 
cyclopeptide was randomly varied with the usage-directed Monte Carlo conformational search. Ring-
closure bonds were defined in the CPA ring and in the cyclopeptide ring. Amide bonds were included 
among the rotatable bonds. For each search, at least 1000 starting structures for each variable torsion 
angle were generated and minimized until the gradient was less than 0.05 kJ/Åmol using the truncated 
Newton-Raphson method implemented in Macromodel. Duplicate conformations and those with an energy 
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